Chevron (CVX) and Exxon Mobil (XOM) released their Q2 and YTD 2024 results on August 2. I reviewed XOM's results in this post and concluded that investor sentiment is insufficiently negative to increase my exposure. Looking at CVX's Q2 2024 results, we see that they fell short of investors' expectations and investor sentiment is somewhat [...]
I last reviewed Intercontinental Exchange (ICE) in my February 10, 2024 post at which time the Q4 and FY2023 results had just been released. With the release of Q2 and YTD2024 results on August 1, 2024 I revisit this existing holding. Business Overview Part 1 of ICE's FY2023 Form 10-K has a comprehensive overview of [...]
I last reviewed Exxon Mobil (XOM) in this December 8 2023 post and concluded that many investors tripping over themselves to acquire shares in the 'Magificent 7' (Alphabet GOOGL, Apple AAPL, Amazon AMZN, Meta Platforms META, Microsoft MSFT, Nvidia NVDA and Tesla TSLA) might get a rude awakening when least expected. On the other hand, [...]
When I last reviewed Mastercard (MA) in this February 20, 2024 post, I concluded that shares were overvalued. On July 25, I disclosed the purchase of 300 V shares in my I Have Increased My Visa Exposure post. On the same day, I increased my MA exposure with the purchase of 300 shares @ ~$432.05; [...]
This FFJ Portfolio - July 2024 report recaps my investment activity during the month. As disclosed in my FFJ Portfolio - June 2024 post, I have made multiple changes to the FFJ Portfolio because of changes to the tax treatment of capital gains in Canada. One of these changes entailed the sale of all shares [...]
The Canadian federal government's proposed increase to the capital gains inclusion rate led us to revisit our estate plans. Based on guidance from our tax accountants, we liquidated all holdings within a specific investment account; I disclosed this in my June 11, 2024 FFJ Portfolio Adjustments Before Capital Gains Tax Changes Arrive post. CME Group [...]
Often times, great companies suffer from temporary headwinds which may present buying opportunities. RTX Corporation (RTX) is a case in point. In 2023, RTX disclosed that its Pratt & Whitney business segment was experiencing significant challenges resulting from microscopic contaminants in a metal used in part of the Geared Turbofan (GTF) engines that power Airbus' [...]
I last reviewed Nasdaq (NDAQ) in this April 26, 2024 post at which time the Q1 2024 results were the most current. Now that we have NDAQ's Q2 and YTD2024 results, I revisit this holding. Business Overview The best way to learn about NDAQ is to review its website. Part 1 Items 1 (Business) and [...]
West Pharmaceutical's (WST) recent share price behavior has given rise to concern by some shareholders. After reviewing the recently released Q2 and YTD2024 results and the transcript of the Q2 earnings call with analysts, my opinion about WST's long term outlook is unchanged. WST remains a good long-term investment despite weaker than expected results and [...]
I last reviewed Thermo Fisher (TMO) in this February 2, 2024 post. In that post, I concluded that short term demand softness would likely pressure Thermo Fisher's valuation. With the recent release of Q2 and YTD2024 results and minor revisions to the FY2024 outlook, I revisit TMO. Business Overview I reviewed material presented at [...]